⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Senolytics
Current understanding
Dasatinib+quercetin, fisetin and successors — clearing senescent cells; early human trials underway.
Evidence log
- 2026-11-12 — The DNA Damage Response Induces PD-L1 Expression and Immune Evasion in Senescent Cells: [mechanism-plausible] News report, with no primary study design or model details supplied, describes DNA-damage-response-induced PD-L1 expression as a mechanism of senescent-cell immune evasion; biology suggests checkpoint blockade could restore immune clearance, but no outcome study supplied confirms this proposed immuno-senolytic strategy or establishes human safety or healthspan benefit. [mechanism-plausible] (novelty: 3)
- 2026-11-01 — Enabling Photoacoustic Imaging and Photothermal Elimination of Senescent Cells via an Activatable Theranostic Probe.: [animal-model] Preclinical in vivo study reports that the SA-β-gal-activated probe RPM-Gal enables selective photoacoustic imaging and light-triggered photothermal elimination of senescent cells, adding an imaging-guided senolytic approach without establishing human safety, efficacy, or longevity benefit. [animal-model] (novelty: 3)
- 2026-11-10 — A Supplement Kills Senescent Cells and Extends Life in Mice: [animal-model] News coverage of a Nature Aging mouse study reports that late-life vanadyl sulfate supplementation selectively cleared senescent cells and improved healthspan and median lifespan in male mice, adding a supplement-based senolytic candidate without establishing human efficacy or safety for longevity use. [animal-model] (novelty: 4)
- 2026-11-10 — Cepharanthine Identified as a Novel Senolytic: [mechanism-plausible] News report, with no primary study details supplied, nominates the plant alkaloid cepharanthine as a selectively cell-clearing senolytic candidate, extending the candidate pipeline without establishing experimental selectivity, animal healthspan effects, or human benefit in the available material. [mechanism-plausible] (novelty: 3)
- 2026-11-09 — Senescence-targeted engineered CAR-T immunotherapy: advances, challenges and perspectives for engineered senolytic immunotherapy.: [expert-opinion] Review, no new primary data: the authors evaluate engineered CAR-T senolytics using existing preclinical clearance and healthspan findings, identifying heterogeneous target antigens and immunosuppressive aged tissue environments as barriers to translation without establishing human healthspan benefit. [expert-opinion] (novelty: 3)
- 2026-03-31 — Reprogramming the mitochondrial-circadian energy code with incretins.: [mechanism-plausible] Review, no new combination outcome data: biology suggests senolytic clearance could complement incretin-linked mitochondrial and circadian effects, but no outcome study presented confirms added healthspan or lifespan benefit or establishes the safety of the proposed multi-intervention combination. [mechanism-plausible] (novelty: 3)
- 2026-11-02 — Fatty acid desaturation controls cellular fate decisions between senescence and ferroptosis.: [animal-model] Cell and aged-mouse study identifies DGLA depletion as a switch favoring senescent-cell persistence and reports that oral DGLA selectively promotes ferroptotic senescent-cell clearance with improved functional outcomes in aged mice, adding a lipid-metabolic senolytic route without establishing human benefit. [animal-model] (novelty: 4)
- 2026-10-29 — Intervening in Adipocyte Senescence: Lipid Prodrugs as an Emerging Strategy for Metabolic Disease Treatment.: [mechanism-plausible] Review proposes lipid prodrugs for selective delivery of senolytics to clear senescent adipocytes in metabolic disease; biology suggests a targeting rationale, but the review supplies no new primary outcome data confirming formulation selectivity, metabolic benefit, or human longevity effects. [mechanism-plausible] (novelty: 3)
- 2026-05-21 — A photo-responsive, fisetin-functionalized DNA nanocage for programmed therapy to accelerate early-stage wound healing in aged skin.: [animal-model] Aged-mouse study reports senescent-cell clearance and accelerated early-stage skin wound healing using photo-programmed delivery of fisetin plus a miR-29-targeting antisense oligonucleotide in a DNA nanocage, extending localized senolytic combination delivery without establishing human efficacy or longevity benefit. [animal-model] (novelty: 3)
- 2026-10-23 — Olfactory Receptor 51E2 Activation by β-Ionone Induces a Senescence-Like Phenotype and Increases Susceptibility to Senolytic Treatment in Colorectal Cancer.: [mechanism-plausible] Preclinical colorectal cancer cell study reports that β-ionone activation of OR51E2 induces a senescence-like phenotype and increases susceptibility to dasatinib plus quercetin, supporting an induce-then-clear oncology strategy without establishing human cancer efficacy or longevity benefit. [mechanism-plausible] (novelty: 3)
- 2026-11-01 — Tree Shrew as an Emerging Model for Aging Research: Characterization of Senescence and Therapeutic Interventions.: [animal-model] Tree shrew aging and dasatinib+quercetin intervention study reports closer concordance with human aging transcriptomes and pathologies than mice and treatment responses described as human-concordant, extending non-rodent senolytic testing without establishing human longevity benefit. [animal-model] (novelty: 4)
- 2026-10-07 — Nanoparticle-based senolytic and senomorphic therapies for healthy aging: design principles, translational evidence, and challenges.: Review of nanoparticle-based senolytic/senomorphic delivery synthesizes design principles (targeted uptake, stimulus-responsive release) and translational status, concluding clinical value still requires matching defined senescent populations to delivery strategies and demonstrating advantage over feasible non-nanoparticle regimens — no new primary outcome data. [expert-opinion] (novelty: 3)
- 2026-10-08 — Biomarker-Guided, Stage-Specific Senotherapy for Metabolic Dysfunction-Associated Steatotic Liver Disease.: Perspective proposes a biomarker-guided, stage-specific MASLD senotherapy sequence in which short-course senolytic clearance is reserved for early disease stages and gated by selection, timing, and response biomarkers — conceptual framing built on existing D+Q MASH trial data, no new primary readout. [expert-opinion] (novelty: 3)
- 2026-09-30 — An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer: Open-label pilot in adult survivors of childhood cancer testing short-course D+Q and fisetin alone on blood p16INK4a and frailty measures (walking speed) — extends the senolytic clinical program into a chemotherapy-accelerated-aging survivor population; design item only, no efficacy readout. [expert-opinion] (novelty: 3)
- 2026-10-01 — Precision Microbiota Interventions for Senoreduction Trial: cross-connection with probiotics-oral-brain: Trial frames GRAS microbiota interventions as a senoreduction strategy, pulling probiotic/prebiotic approaches into the same outcome space as classical senolytic programs via immune-senescence biomarkers. (novelty: 3)
- 2026-10-01 — Endothelial TLR4 at the Crossroads of Vascular Senescence and Targeted Senotherapeutics.: Conceptual review reframes endothelial TLR4 as a cell-type- and context-specific driver of vascular senescence and proposes endothelium-targeted senolytic delivery (VCAM-1/E-selectin nanoparticles, engineered plant exosomes) after systemic pan-TLR4 blockade failures — delivery/mechanism framing, no new primary data. [mechanism-plausible] (novelty: 3)
- 2026-10-05 — Decline of chaperone-mediated autophagy in aging impairs macrophage clearance of senescent cells.: cross-connection with cma-activators: CMA activation offers an immune-mediated route to senescent-cell clearance (restoring macrophage function), mechanistically distinct from direct senolytic killing — a potential complement or alternative to small-molecule senolytics. (novelty: 4)
- 2026-10-05 — Therapeutic reversal of cellular senescence: A systematic review of senolytics, senomorphics and anti-ageing therapies in human clinical trials.: PRISMA systematic review of completed human clinical trials of senolytics (chiefly dasatinib+quercetin) concludes that preliminary biological and functional signals exist in humans but completed trial numbers are small and evidence is insufficient to establish clinical efficacy or long-term safety — synthesis of existing trial literature, no new primary data. [expert-opinion] (novelty: 3)
- 2026-10-05 — Senotherapeutic potential against xeroderma pigmentosum.: iPSC-derived melanocyte drug screen in xeroderma pigmentosum: BCL-2-like and HSP90 inhibitors cleared UV-induced senescent XP patient melanocytes, extending the senolytic class into a monogenic photoaging indication — preclinical cell model only, no in vivo or human data. [mechanism-plausible] (novelty: 3)
- 2026-10-01 — Novel Flavonoid Senotherapeutics Identified by Phenotypic Drug Discovery Reduce Senescence and Improve Multiple Markers of Healthspan.: Phenotypic drug-discovery screen in aging mice: novel fisetin-derived flavonoid senolytics SR29384 and SR31133 showed broader activity across senescent cell types, reduced tissue senescence, and improved multiple healthspan markers — extends the natural-flavonoid senolytic scaffold beyond fisetin itself with preclinical compound-level progress, no human data. [animal-model] [animal-model] (novelty: 3)
- 2026-09-28 — Functional Shift of NLRP3 Inflammasome Activity in Aged Macrophages.: cross-connection with nlrp3-inhibitors: If NLRP3 inhibition expands the senescent cell pool in aged macrophages, chronic NLRP3 blockade could create a mechanistic rationale for pairing with — or at least monitoring against — senolytic clearance strategies. (novelty: 3)
- 2026-07-14 — A compendium of circulating biomarkers of senescence in humans: Insights on mechanistic impact across health domains and modulation by therapeutic interventions.: Human-focused compendium review consolidates circulating SASP factors (notably GDF15 and Activin A) as candidate noninvasive readouts of senescence burden across neurodegenerative, pulmonary, cardiometabolic, and musculoskeletal domains, and catalogs how emerging senotherapeutics modulate these markers — synthesis of existing biomarker literature, no new primary outcome data. [expert-opinion] (novelty: 3)
- 2026-09-29 — Autologous cytokine-induced NK cells as candidate cellular senolytics: evidence, obstacles, and the experiments still needed.: Review reframes autologous cytokine-induced NK cells as a candidate cellular senolytic modality and specifies gating experiments (autologous cytotoxicity against senescent targets, preclinical infusion studies) that should precede any first-in-human program — no new primary data. [mechanism-plausible] (novelty: 3)
- 2026-08-10 — Chronic subdural hematoma through the hallmarks of aging: a geroscience framework for the commonest neurosurgical condition of older adults.: Minireview mapping chronic subdural hematoma onto the twelve hallmarks of aging nominates senolytics as a mechanism-directed gerotherapeutic candidate for CSDH, citing chronic inflammation and altered intercellular communication as the hallmarks with strongest CSDH support — conceptual extension into a common neurosurgical condition of older adults, no primary outcome data. [mechanism-plausible] (novelty: 3)
- 2026-09-29 — Long-Term Human Skin Platform for Modeling Chronic Inflammation, Environmental Stress, and Therapeutic Intervention.: Long-term (up to 4 weeks) human skin explant platform study: senolytic-associated treatment reduced SASP factors in aged human skin tissue ex vivo, extending senolytic rationale to a human-tissue (not in vivo) chronic-inflammation/senescence readout. [mechanism-plausible] (novelty: 3)
- 2026-04-02 — Ceramic-based biomaterials: Combining regeneration with anti-senescence.: Preclinical osteoporotic bone-regeneration study positions ZnCS silicate bioceramics as an implant-based anti-senescence modality that reportedly outperformed systemic dasatinib+quercetin on BMSC senescence and bone regeneration endpoints via PI3K–AKT–SIRT1 — extends the senolytic/senotherapy landscape with a biomaterial-delivered, locally acting alternative to small-molecule D+Q. [animal-model] (novelty: 4)
- 2026-06-22 — Targeting Cellular Senescence Enhances Post-Burn Wound Healing in Aged Mice.: Aged-mouse burn-wound study: dasatinib+quercetin cleared senescent cells at burn sites and improved macroscopic healing, myofibroblast markers, and type I collagen deposition versus untreated aged burns — extends D+Q rationale into age-impaired acute wound (burn) repair. [animal-model] (novelty: 3)
- 2026-10-01 — Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial.: Phase-2 proof-of-principle RCT of intermittent dasatinib+quercetin in fibrotic MASH (paired biopsy): fibrosis improved ≥1 stage without MASH worsening in 47% on D+Q vs 7% on placebo, with higher MASH-resolution rates and snRNA-seq evidence of reduced senescent and fibrogenic populations — first human RCT outcome data for D+Q in a fibrotic organ disease. [human-rct] (novelty: 4)
- 2026-01-25 — Targeted delivery of senolytic drugs using macrophage membrane-camouflaged magnetic nanoparticles inhibits endplate sclerosis.: LSI mouse study: macrophage-membrane-camouflaged magnetic nanoparticles loaded with ABT-263 dual-target senescent-like macrophages in degenerating vertebral endplates, suppressing IL-10–driven angiogenesis–osteogenesis coupling and alleviating endplate sclerosis — extends biomimetic/magnetic targeted senolytic delivery into a low back pain indication. [animal-model] (novelty: 3)
- 2026-06-04 — Targeting NFAT5 attenuates high sodium-induced vascular aging by re-sensitizing senescent smooth muscle cells to apoptosis.: Mouse + cell study: high dietary sodium drives vascular smooth-muscle cell senescence via NFAT5-dependent Bcl-XL transcription that renders senescent VSMCs apoptosis-resistant; the NFAT5 inhibitor KRN5 restores apoptosis sensitivity and acts as a senolytic, nominating NFAT5–Bcl-XL as a new vascular-aging senolytic axis distinct from direct BCL-2/BCL-XL inhibition. [animal-model] (novelty: 3)
- 2026-10-01 — uPAR-Targeting T Cell Engager Exerts Senolytic Effects in Mice and Non-Human Primates With Serum Aminotransferase Activity as a Safety Monitor.: Mouse + non-human primate preclinical package: a uPAR-targeting GFD-CD3 bispecific T-cell engager eliminated senescent cells and alleviated age-related pathologies with serum aminotransferase monitoring guiding safe dose titration — extends the immuno-senolytic branch with a titratable off-the-shelf alternative to senolytic CAR-T, no human data. [animal-model] (novelty: 4)
- 2026-10-04 — Orthogonal Light- and Enzyme-Triggered and-Gate Prodrugs for Senolytic Therapy.: In vitro + patient-derived organoid proof-of-concept: a dual-trigger AND-gate prodrug (390 nm light + SA-β-gal cleavage) releases doxorubicin or ARV-771 PROTAC payloads preferentially in senescent cells, improving senolytic index over the parent drugs — a delivery-selectivity advance for the senolytic class, no in vivo or human data. [mechanism-plausible] (novelty: 3)
- 2026-05-28 — Feedback loops between DNMT1 and autophagy as well as senescence promotes organ aging and canities.: Mouse mechanistic study: DNMT1 protein rises in aged tissues (despite falling mRNA) and methylates autophagy-, senescence-, and melanin-related genes, forming reversible feedback loops that senolytic clearance (alongside DNMT1 inhibition) breaks — extends senolytic rationale upstream into a DNA-methylation feedback circuit driving organ aging and canities. [animal-model] (novelty: 3)
- 2026-09-25 — Fisetin to Improve Vascular Function in Older Adults: Pilot RCT of intermittent fisetin in older adults targets vascular endothelial function and aortic stiffness with senescence/SASP and mitochondrial oxidative stress mechanistic endpoints — extends the senolytic clinical program into a vascular-aging indication; no efficacy data yet. [expert-opinion] (novelty: 3)
- 2026-09-14 — Clearance of p16-positive cardiac cells improves age-related cardiac remodeling in mice.: Mouse genetic p16+ cell clearance from midlife to old age attenuated age-related left-ventricular hypertrophy, wall thickening, and diastolic dysfunction, implicating senescent cardiac fibroblasts and cardiomyocytes with a fibroblast-to-cardiomyocyte paracrine hypertrophy link. [animal-model] (novelty: 3)
- 2026-09-15 — LSD1-mediated demethylation of the DNA damage response factor ATM promotes senescence and organ aging.: Preclinical LSD1–ATM K3016 study reports an autophagy–LSD1 feedback loop that positions LSD1 inhibition as a mechanistically distinct senolytic-adjacent lever — reducing senescent-cell accumulation via enhanced DNA repair rather than direct senescent-cell killing. [animal-model] (novelty: 4)
- 2026-09-23 — Engineered Extracellular Vesicle Revitalizing Macrophage Energy Metabolism for Aged Wound Repair.: Aged/diabetic mouse wound-healing study: 4OI-engineered extracellular vesicles reversed macrophage senescence and improved wound repair by restoring arginine–OXPHOS metabolism through ASS1 — extends the senotherapy landscape with a non-killing, metabolism-restoring modality that reverses (rather than clears) senescent macrophages. [animal-model] (novelty: 3)
- 2026-09-15 — Radiation-induced atrial fibrillation is driven by cellular senescence via the GATA4 - NF-κB pathway and rescued by D/Q senolytic therapy.: Mouse study: ionizing radiation drove atrial remodeling and AF susceptibility via GATA4–NF-κB–SASP-mediated cellular senescence, and dasatinib+quercetin reversed the atrial phenotype — extends D+Q senolytic rationale into a cardio-oncology (radiation-induced atrial fibrillation) indication. [animal-model] (novelty: 3)
- 2026-09-18 — Cellular senescence is an early feature and therapeutic target in amyotrophic lateral sclerosis TDP-43mice.: TDP-43 ALS mouse study: dasatinib+quercetin improved motor behavior and neuromuscular function, lowered plasma neurofilament light chain, and preserved layer V motor cortex neurons, with cellular senescence markers appearing early in motor cortex and spinal cord — extends D+Q rationale into ALS motor neurodegeneration. [animal-model] (novelty: 3)
- 2026-06-23 — Hydrogel-based senomorphic approaches to modulate cellular senescence and promote tissue rejuvenation.: Same hydrogel-senotherapy review contrasts localized senomorphic hydrogels with cell-killing senolytic approaches, positioning sustained SASP suppression via biomaterial delivery as a resident-cell-sparing alternative in tissues where senescent-cell clearance risks depleting limited regenerative pools — conceptual framing, no primary outcome data. [mechanism-plausible] (novelty: 3)
- 2026-07-13 — Nanoparticles as an efficient strategy to eliminate senescent brain endothelial cells.: Naturally aged rat study: SA-β-gal-responsive polymeric nanoparticles loaded with navitoclax selectively cleared p16/p21+ brain endothelial cells, reduced blood-brain barrier permeability, and partially restored exploratory behavior at lower doses than free navitoclax — extends targeted senolytic delivery to the cerebrovascular endothelium. [animal-model] (novelty: 3)
- 2026-08-28 — Senescent cells maintain viability through adhesion-dependent fragmentation that promotes debris deposition.: Preclinical cell-biology study identifies senescent cell adhesion-dependent fragments (SCAFs) as a survival mechanism: senescent cells shed organelle-rich, mitochondria-laden fragments that rupture extracellularly to deposit DAMPs, amyloid-like material, and neurodegeneration-linked proteins driving migration, invasion, and inflammatory signaling — nominates SCAF shedding as a distinct upstream target beyond direct senescent-cell killing. [mechanism-plausible] (novelty: 4)
- 2026-09-10 — Blocking PD-L2 prevents senescent cell accumulation and age-related dysfunction.: Aged-mouse study: PD-L2 blockade (antibody and knockout) reduced senescent-cell accumulation and improved insulin sensitivity and grip strength by disabling an immune-evasion checkpoint on senescent cells — extends the senolytic class with a checkpoint-inhibitor axis that clears senescent cells via endogenous immunity rather than direct killing. [animal-model] (novelty: 4)
- 2026-09-11 — Mitochondrial homeostasis in musculoskeletal diseases: From pathogenic mechanisms to precision therapies.: Same review integrates senolytics into a mitochondrial-homeostasis framework for OP/OA/RA, framing SASP-driven mitochondrial dysfunction in senescent chondrocytes, osteocytes, and synoviocytes as a mechanism-matched senolytic indication — conceptual synthesis, no new MSK outcome data. [mechanism-plausible] (novelty: 3)
- 2026-07-17 — Cellular Senescence and COVID-19 Long-Hauler Syndrome: Translational rationale piece proposes senescent-cell/SASP accumulation as a contributor to COVID-19 Long-Hauler Syndrome and floats a senolytic clinical trial as the next step — extends the senolytic clinical program into post-viral syndrome, no efficacy data. [mechanism-plausible] (novelty: 3)
- 2026-07-30 — Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors: Phase II trial launched combining fisetin with exercise for frailty prevention in breast cancer survivors — extends the senolytic clinical program into a chemotherapy-accelerated-aging subpopulation and pairs a senolytic with an exercise co-intervention; design item only, no efficacy data. [expert-opinion] (novelty: 3)
- 2026-08-10 — Evaluation of Urolithin A and Fisetin on Improving Sleep and Aging Biomarkers: 12-week RCT protocol registered testing fisetin 500 mg (with urolithin A mono and combination arms) for sleep quality and aging biomarkers in middle-aged/older adults — extends the senolytic clinical program to a sleep-plus-biomarker endpoint, no efficacy data yet. [expert-opinion] (novelty: 3)
- 2026-09-10 — Inhibition of the PGAM1-CHK1 Interaction as a Novel Approach to Destroy Senescent Cells: News-report coverage of a preclinical finding proposing disruption of the PGAM1–CHK1 interaction as a metabolic senolytic strategy that sabotages the elevated glycolysis of senescent cells — adds a new metabolic-vulnerability branch to the senolytic class, no human data. [mechanism-plausible] (novelty: 3)
- 2026-05-07 — FMO1 disrupts mitochondrial functional homeostasis through ROS-mediated mechanisms to drive chondrocyte senescence and hypertrophy.: Preclinical chondrocyte senescence/hypertrophy study: ABT-263 (navitoclax) senolytic clearance reduced FMO1–ROS–mitochondrial-fission-driven p16/p21+ chondrocytes and abnormal hypertrophy, extending navitoclax rationale into cartilage aging alongside upstream FMO1 inhibition. [animal-model] (novelty: 3)
- 2026-09-01 — NADMetabolic Reprogramming Drives CD8T Cells Senescence and Exacerbates Ulcerative Colitis.: Preclinical UC study: clearing NAD-depleted, mtDNA–cGAS–STING-driven senescent CD8 T cells with senolytics attenuated ulcerative colitis in mice, with parallel human correlations between the senescent-CD8 signature and disease severity/treatment non-response — extends senolytic rationale into IBD immunosenescence, no primary human outcome data. [animal-model] (novelty: 3)
- 2026-07-17 — Improving Physical Ability and Cellular Senescence Elimination in HIV: Phase II placebo-controlled RCT launched testing intermittent dasatinib+quercetin over 12 weeks in frail/prefrail adults 50+ with long-term ART-suppressed HIV, targeting physical function and cellular senescence — extends the D+Q clinical program into an accelerated-aging population; design item only, no efficacy readout. [expert-opinion] (novelty: 3)
- 2026-07-01 — Ongoing Lung Decline With Age Intensified Response: Phase II pilot RCT launched (adults 60+, smokers and never-smokers) testing intermittent high-dose fisetin for lung function and senescence biomarkers — extends the senolytic clinical-probe program into age-related pulmonary decline; no results yet. [expert-opinion] (novelty: 3)
- 2026-08-27 — Timing‐Dependent Clearance of p16‐Positive Cells Mitigates Radiation‐Induced Accelerated Aging: Preclinical radiation-induced accelerated aging model: timing of p16+ senescent-cell clearance determined efficacy, indicating that when senolytics are dosed relative to injury—not just whether—modulates protection against radiation-driven aging phenotypes. [animal-model] (novelty: 3)
- 2026-03-25 — Senolytic therapy ameliorates high-fat diet-induced hippocampal senescence and cognitive decline in mice.: HFD/palmitate mouse study: dasatinib+quercetin reversed hippocampal cellular senescence and cognitive decline induced by high-fat diet, extending the D+Q senolytic rationale into obesity-driven neurodegeneration. [animal-model] (novelty: 3)
- 2026-04-15 — Tubeimoside Ⅰ targets sodium/potassium ATPase alpha 1 subunit to selectively eliminate senescent cells and alleviate aging-associated abnormalities.: Mouse study (radiation-induced and naturally aged): the triterpenoid saponin Tubeimoside I selectively cleared senescent cells via ATP1A1 (Na+/K+ ATPase α1) binding and K+/ion-homeostasis disruption, improving motor function and lowering senescence markers without clear toxicity — adds a new mechanistic branch (ion-pump targeting) to the senolytic class beyond D+Q, fisetin, navitoclax, and PCC1. [animal-model] (novelty: 3)
- 2026-05-20 — Senescent Cell Derived Artificial Vesicle-Based Senolytic Sonovaccine Platform with Augmented Lymph Node Delivery and Antigen Cross-Presentation Efficacy.: ApoE mouse atherosclerosis study: SenoVac, an albumin-hitchhiking DBCO/azide senescent-cell artificial vesicle vaccine co-loaded with HMME and R848, achieved lymph-node delivery and ultrasound-triggered CD8 T-cell cross-presentation to clear plaque senescent cells and attenuate atherosclerosis — extends senolytic immunotherapy into a modular sono-vaccine platform. [animal-model] (novelty: 3)
- 2026-05-25 — Pathological Mechanism-Inspired Biomimetic Nano-Senotherapy for Reversing Experimental Atherosclerosis in ApoEMice.: ApoE mouse atherosclerosis study: a neutrophil-membrane-cloaked, ROS-responsive nanocarrier co-delivering an MPO-inhibitory KYC dimer prodrug with navitoclax reversed established plaques by both preventing new senescent-cell formation and clearing existing ones — extends the block-and-clear senolytic paradigm with a biomimetic targeted-delivery platform in vascular aging. [animal-model] (novelty: 3)
- 2026-05-30 — Cell senescence in chronic pain: An integrative perspective on cellular and neural mechanisms.: Integrative review nominates senolytics as a candidate therapy for chronic pain by clearing senescent cells across pain-processing tissues (neurons, glia, immune, joint) that sustain pain via SASP, mitochondrial dysfunction, and epigenetic changes — conceptual cross-domain extension, no primary human pain outcome data. [mechanism-plausible] (novelty: 3)
- 2026-06-03 — Senolytics ameliorate cognitive decline in D-galactose-induced aging mice by inhibiting astrocytic cholesterol accumulation.: D-galactose aging-mouse study: dasatinib+quercetin reversed cognitive decline by suppressing astrocytic cholesterol biosynthesis, reducing lipid accumulation and neuroinflammation, with multi-omics and causal genetic/pharmacologic reversal — extends D+Q rationale to a lipid-metabolic mechanism in brain aging. [animal-model] (novelty: 3)
- 2026-06-12 — Chimeric Antigen Receptor T Cells as Living Therapeutics Targeting Senescence and Age-Related Diseases.: Systematic review positions CAR T cells engineered against senescent-cell surface antigens as a next-generation, more selective and durable senolytic modality than small-molecule D+Q/fisetin, citing preclinical fibrosis reversal and metabolic improvement but no primary human efficacy data. [mechanism-plausible] (novelty: 3)
- 2026-06-12 — Hematopoietic Rejuvenation via Natural Senolytic NSPCC1 Delays Inflammatory Aging.: Two-model mouse aging study: oral NSPCC1 (bioavailability-enhanced grape-seed PCC1) extended lifespan, rejuvenated hematopoietic stem/progenitor cells, and reduced multi-organ inflammatory aging phenotypes — extends the natural-senolytic branch beyond fisetin/quercetin/D+Q with an HSPC-rejuvenation and inflammaging readout. [animal-model] (novelty: 3)
- 2026-07-01 — Podocyte mPGES-2 Determines Renal Aging and Contributes to Senile Osteoporosis.: cross-connection with mpges2-inhibitors: Both target senescent cell burden as a driver of age-related decline; mPGES-2 inhibition acts upstream by suppressing PGE/EP1-mediated podocyte senescence rather than clearing senescent cells. (novelty: 3)
- 2026-06-27 — Co-exposure to environmental lead and hypertension exacerbates anxiety and depression via mtDNA-mediated cGAS phase separation.: Mouse co-exposure study (lead + hypertension): dasatinib+quercetin alleviated anxiety- and depression-like behavior by clearing prefrontal astrocyte senescence driven by cytosolic mtDNA–cGAS phase separation, extending the D+Q rationale into an environmental–cardiometabolic comorbidity model of neurobehavioral aging. [animal-model] (novelty: 3)
- 2026-07-01 — Targeting YAP1-Mediated Tubular Cell Senescence to Attenuate Maladaptive Repair and Fibrotic Transition After Acute Kidney Injury.: AKI-to-CKD mouse/in vitro study: post-injury senolytic dosing (initiated Day 3) suppressed sustained YAP1-driven tubular senescence and attenuated maladaptive repair and progression to renal fibrosis, extending the senolytic rationale to a specific YAP1/tubular-senescence axis in kidney fibrotic transition. [animal-model] (novelty: 3)
- 2026-04-30 — Damage-induced muscle regeneration after exercise in humans: Modulatory effects of ginsenoside Rg1.: Review nominates ginsenoside Rg1 as a candidate senolytic acting on exercise-induced muscle damage, citing human biopsy signals for clearing injury-associated senescent cells — conceptual extension of the senolytic rationale into skeletal-muscle regeneration, no new primary outcome data. [mechanism-plausible] (novelty: 3)
- 2026-06-17 — Resetting the epigenetic clock: cellular senescence and regenerative strategies in intervertebral disc degeneration.: Narrative review of intervertebral disc degeneration frames IDD as an epigenetic-clock/SASP disease and proposes a sequential ‘clear–prime–seed’ roadmap (senolytic clearance → epigenetic remodeling → cellular reprogramming), positioning senolytics as the first step of a tissue-specific regenerative sequence for the disc; conceptual synthesis, no new primary IDD outcome data. [mechanism-plausible] (novelty: 3)
- 2026-07-01 — The Molecular Basis of Ocular Aging: Mechanisms, Pathologies, and Emerging Therapeutics.: Ocular aging review nominates senolytic clearance of senescent RPE, trabecular meshwork, and neurovascular cells as an emerging strategy across AMD, glaucoma, and diabetic retinopathy — conceptual synthesis, no new primary ocular outcome data. [mechanism-plausible] (novelty: 3)
- 2026-07-16 — Age-associated decline of Lamtor5 drives immunosenescence and systemic aging via cGAS-mediated paracrine inflammation.: Aged-mouse Lamtor5/cGAS study: senolytic treatment recapitulated the anti-aging benefits of macrophage-targeted cGAS blockade, positioning clearance of cGAS-inflamed senescent macrophages as convergent with direct pathway inhibition on the immunosenescence axis. [animal-model] (novelty: 3)
- 2026-07-17 — Manganese overload as a previously underappreciated trigger of cellular senescence: Unraveling mechanisms and therapeutic rescue by the senolytic quercetin.: C. elegans + PC12 study nominates manganese overload as a previously underappreciated senescence trigger (oxidative stress, mitochondrial dysfunction, telomere attrition, p53/p21, STING) rescuable by quercetin — extends the senolytic rationale to environmental metal-driven senescence. [animal-model] (novelty: 3)
- 2026-07-18 — Chemotherapy-induced senescence promotes stroma stiffness and antioxidant adaptation to promote chemoresistance in pancreatic ductal adenocarcinoma.: PDAC mouse study: gemcitabine-induced tumor-cell senescence stiffened stroma via SASP/Piezo1 and engaged a BRG1–NRF2–SLC7A11 antioxidant program that suppressed ferroptosis and drove chemoresistance; combining the senolytic ABT-263 (navitoclax) with the ferroptosis inducer Erastin reversed resistance in vivo — extends senolytic rationale to a chemoresistance/ferroptosis combination axis in an oncology (not healthspan) context. [animal-model] (novelty: 3)
- 2026-07-20 — Theca cells: active orchestrators of ovarian aging.: Review repositioning theca cells as active drivers of ovarian aging nominates senolytic clearance of senescent theca cells as a translational priority to preserve estrogen biosynthesis and blunt follicular atresia and fibrosis; conceptual reframing built on preclinical rescue data, no new outcome data. [mechanism-plausible] (novelty: 3)
- 2026-08-01 — Ammonia Metabolism in the Aging Liver: Emerging Mechanistic Insights.: Ammonia-in-aging review nominates hepatic ammonia accumulation as an upstream driver of hepatocyte and multi-organ senescence, framing ammonia-lowering strategies as potentially complementary to senolytic clearance by cutting off a senescence-provoking stress signal; conceptual reframing, no new outcome data. [mechanism-plausible] (novelty: 3)
- 2026-07-29 — Complosome as a key modulator of cellular senescence, aging and age-related diseases.: Review frames the intracellular complement system (complosome; intC3/intC5) as an upstream modulator of cellular senescence via crosstalk with mTOR, NF-κB, and AMPK, positioning complosome-targeted agents as a potential upstream complement to direct senescent-cell clearance — mechanistic synthesis, no new outcome data. [mechanism-plausible] (novelty: 3)
- 2026-07-15 — Osteoimmune senescence in aging-related bone diseases.: Review consolidates ‘osteoimmune senescence’ as a shared framework across osteoporosis, OA, RA erosion, periodontal bone loss, and fracture healing, framing senescent skeletal cells, chronic SASP, and impaired immune clearance as a common target set for senolytic/senomorphic strategies in age-related bone disease; conceptual synthesis, no new outcome data. [expert-opinion] (novelty: 3)
- 2026-07-31 — The Physical Senotype in cellular senescence: Mechanical and physical strategies for senotherapy.: Review proposes a ‘Physical Senotype’—a shared but heterogeneous loss of mechanical plasticity across senescent cells—and surveys early-stage physical/mechanical senotherapies (mechanical, ultrasound, thermal, optical) intended to kill, clear, or reprogram senescent cells; conceptual framework with unresolved specificity and safety, no new outcome data. [mechanism-plausible] (novelty: 3)
- 2026-08-07 — Cellular senescence in posterior segment neovascular diseases: A proposed feed-forward amplification model.: Hypothesis-generating review proposes cellular senescence as a feed-forward amplifier of angiogenic, inflammatory, and fibrotic dysfunction in neovascular AMD and proliferative diabetic retinopathy, nominating senolytics and SASP modulators as potential anti-VEGF adjuncts — mechanistic reframing, no new primary ocular outcome data. [mechanism-plausible] (novelty: 3)
- 2026-08-05 — The Immunometabolic Bridge: Targeting Metainflammation to Prevent the Transition from Obesity to Cardiovascular Disease.: Same review places senolytics at the top rung of an obesity-to-CVD prevention ladder, framing them as reserved for the metainflammation stage once lifestyle/statins and GLP-1 agonists have not resolved adipose-driven senescent-cell accumulation; conceptual synthesis, no new outcome data. [expert-opinion] (novelty: 3)
- 2026-08-10 — Fibrillarin Resists Cellular Senescence Via SIRT1-Dependent Nicotinamide Metabolism and Its Inhibition Sensitizes Senolytic Therapy in Esophageal Squamous Cell Carcinoma.: ESCC preclinical study: fibrillarin (FBL) stabilizes SIRT1 and sustains nicotinamide metabolism to resist senescence, and FBL inhibition sensitizes tumor cells to senolytic therapy — nominates FBL as an upstream lever to expand senolytic efficacy, though evidence is cancer-preclinical rather than a healthspan readout. [animal-model] (novelty: 3)
- 2026-08-10 — Youthfulness of marrow Adipoqcells maintained by Cbfβ facilitates stem cell-based bone repair.: Aged-mouse fracture-repair study: Cbfβ loss in marrow Adipoq+ cells reduced chromatin accessibility at DNA-repair loci, driving BMAC senescence/SASP and impaired skeletal stem/progenitor-mediated bone repair; senolytic treatment (as well as AAV-Cbfβ overexpression) rescued fracture healing — extends senolytic rationale to age-related bone repair via a marrow-adipocyte senescence niche. [animal-model] (novelty: 3)
- 2026-08-01 — Cardiometabolic Aging Driven by Multi-Organ Crosstalk: Mechanisms and Therapeutic Strategies.: Narrative review on cardiometabolic aging frames cardiac senescence as a product of multi-organ crosstalk (adipose–heart, muscle–heart, gut–heart, kidney–heart) and nominates senolytics as a nodal intervention converging on shared oxidative-stress/autophagy/senescence pathways; conceptual synthesis, no new outcome data. [expert-opinion] (novelty: 3)
- 2026-08-17 — Ovarian aging and systemic health: Mechanisms and emerging intervention strategies.: Review of ovarian aging and systemic health frames ovary-targeted senolytics as a strategy to clear SASP-bearing ovarian cells, preserve fertility, and potentially extend female healthspan via the ovarian–systemic aging axis; conceptual synthesis, no new outcome data. [expert-opinion] (novelty: 3)
- 2026-08-26 — Triple-pathway synergistic senolysis via AKAP1 silencing and calcium overload: An aptamer-functionalized DNAzyme nanoplatform for anti-pulmonary fibrosis research.: Bleomycin mouse IPF study: L1CAM-aptamer-functionalized DNAzyme/CaCO3 nanoplatform silenced AKAP1 and triggered mitochondrial calcium overload to selectively clear senescent alveolar type II cells and attenuate pulmonary fibrosis without overt toxicity — extends targeted senolytic delivery into lung fibrosis via a triple-pathway (aptamer targeting + gene silencing + Ca2+ overload) design. [animal-model] (novelty: 3)
- 2026-09-01 — Solute Carrier Family 1 Member 5 (SLC1A5)-dependent glutamine transport regulates macrophage senescence and efferocytosis during liver regeneration.: Mouse partial-hepatectomy study: quercetin rescued defective liver regeneration in a model where macrophage SLC1A5 loss caused glutamine-deprivation–driven macrophage senescence and impaired Gas6-mediated efferocytosis — extends senolytic rationale to regenerative failure via clearance of senescent tissue macrophages. [animal-model] (novelty: 3)
- 2026-08-18 — Spatial niche remodeling of senescent liver-resident immune cells and its role in chronic liver diseases.: Review synthesizing liver-resident immune-cell senescence (p53/p21, p16/Rb, mtDNA–cGAS–STING SASP) as spatially organized niche remodeling along the portal–central axis in chronic liver disease, arguing for subset-specific senotherapeutics rather than pan-senolytic clearance; conceptual framework, no new outcome data. [expert-opinion] (novelty: 3)
- 2026-06-19 — Centenarian SIRT6 variants elevate SIRT6 protein and enhance cellular senescence resistance.: cross-connection with sirt6-gene-therapy: Centenarian SIRT6 variants enhance cellular senescence resistance, positioning SIRT6 augmentation as a senescence-prevention approach complementary to senolytic clearance of already-senescent cells. (novelty: 4)
- 2026-06-17 — Synergistic nanosenolytic therapy reverses age-related dry eye disease by targeting cellular senescence and oxidative stress.: Aged-mouse dry eye study: pH-responsive polypeptide nanocarrier eye drops co-encapsulating quercetin and SOD improved corneal delivery, suppressed SASP and oxidative stress, and reversed dry eye manifestations — extending local senolytic delivery to an ocular surface indication. [animal-model] (novelty: 3)
- 2026-07-01 — Multi-omics profiling reveals systemic rejuvenation of the aged kidney through senolytic therapy.: Naturally aged mouse kidney study: long-term dasatinib+quercetin cleared senescent renal cells and, on multi-omics (proteomic + single-cell) profiling, restored Klotho, reactivated PPARα/fatty-acid oxidation, and normalized aging and inflammatory cell-cell communication signatures — extending D+Q from senescence-marker readouts to systems-level renal rejuvenation. [animal-model] (novelty: 3)
- 2026-07-13 — HMGCR-Driven Cholesterol Metabolism Promotes Osteoarthritis Progression by Accelerating Synovial Fibroblast Senescence.: cross-connection with hmgcr-inhibitors: HMGCR blockade reverses synovial fibroblast senescence in OA mice, positioning cholesterol-biosynthesis inhibition as a senomorphic-adjacent strategy alongside classical senolytic approaches. (novelty: 3)
- 2026-07-13 — Enhancing insulin sensitivity by reducing adipocyte senescence using uPAR-targeted nanoparticles in high-fat-diet-induced obese mice.: HFD obese mouse study: uPAR-targeted nanoparticles co-delivering dasatinib+quercetin selectively cleared senescent adipocytes and improved insulin sensitivity, offering a targeted-delivery refinement of the D+Q senolytic paradigm to reduce off-target exposure. [animal-model] (novelty: 3)
- 2026-07-01 — Screening and Activity Profiling of Antisenescence Peptides from Silkworm Pupa Protein Hydrolysate: Discovery of a Bioactive Hexapeptide FKVPNM.: cross-connection with silkworm-pupa-protein-hydrolysate: FKVPNM lowers senescence markers (SA-β-gal) in cell models, positioning it alongside classical senolytic/senomorphic candidates, though no in vivo senescent-cell clearance data exist. (novelty: 3)
- 2026-07-16 — Prevention of Vascular Aging as a Novel Paradigm for GLP-1 Receptor Agonist-Mediated Cardioprotection.: cross-connection with glp1-agonists: Both are framed as acting on senescence-associated inflammation (SASP) in vascular tissue, but from opposite ends: senolytics clear senescent cells directly, while GLP-1RAs are proposed to limit SASP-driven vascular aging as a side effect of cardiometabolic action. (novelty: 3)
- 2026-07-23 — Exercise attenuates atherosclerosis by inhibiting eWAT aging via targeting SIRT1/pyruvate carboxylase pathway.: Mouse HFD study: exercise attenuated atherosclerosis by suppressing epididymal WAT senescence via a SIRT1/pyruvate carboxylase axis, and senolytic treatment or PC knockdown partially recapitulated the vascular protection — extending the senolytic rationale to atherosclerosis via adipose senescence. [animal-model] (novelty: 3)
- 2026-08-10 — Dioscin extends lifespan and ameliorates aging associated phenotypes in association with the endoplasmic reticulum unfolded protein response.: cross-connection with dioscin: Dioscin lowers p16/p21 senescence markers in aged mice, overlapping the senescence-burden endpoint targeted by canonical senolytics though via a distinct ER-UPR proteostasis mechanism rather than selective senescent-cell clearance. (novelty: 3)
- 2026-08-07 — Stress management by benzodiazepines in septic shock and critical illness: mechanistic and clinical evidence supporting alternative sedative strategies.: cross-connection with benzodiazepines: Review posits benzodiazepine-driven senescence accumulation in critically ill patients, connecting sedation choice to the same senescent-cell burden that senolytics target. (novelty: 3)
- 2026-08-03 — Natural Bioactive Compounds Targeting Key Hallmarks of Aging: Functional Food Potential of Spermidine, Fisetin, Berberine, and Urolithin A.: Narrative review reiterates fisetin’s senolytic role within a proposed multi-compound functional-food framework spanning autophagy, senolysis, metabolism, and mitophagy; adds framing but no new senolytic outcome data. [mechanism-plausible] (novelty: 3)
- 2026-08-01 — An ANGPTL8-AKT2-mTOR Axis Drives Adipose Senescence and Aging-Related Functional Decline.: cross-connection with angptl8-inhibitors: ANGPTL8 deletion reduces adipose senescence markers, suggesting upstream suppression of senescent-cell accumulation as an alternative to senolytic clearance. (novelty: 4)
- 2026-08-01 — The Mechanistic Study of Melatonin Regulation of p16Ink4a and Oct4 in Anti-Cellular Senescence.: cross-connection with melatonin: Mechanistic overlap: melatonin lowers the senescence marker p16Ink4a in osteoblast/BMSC models, adjacent to the senolytic/senomorphic target space though via receptor signaling rather than senescent-cell clearance. (novelty: 3)
- 2026-08-11 — Senolytic Treatment Triggered by Carotid Occlusion Confers Protection Against Later Acute Ischemic Stroke in Aged Rats.: Aged-rat study: chronic dasatinib+quercetin started after carotid artery occlusion reduced infarct size, spreading-depolarization frequency, and cerebrovascular senescence markers on subsequent acute ischemic stroke — extends D+Q rationale into stroke resilience in a comorbid aging model. [animal-model] (novelty: 3)
Open questions
Related
Contributing findings
Cellular senescence and the hallmarks of ageing: Evaluating evidence for a causal mechanistic role.
13-nov-2026
novelty 3
per-area 2
mentions
The DNA Damage Response Induces PD-L1 Expression and Immune Evasion in Senescent Cells
12-nov-2026
novelty 3
per-area 3
strengthens
Senescence-Associated Secretory Phenotype (SASP) and Atherosclerotic Plaque Inflammation: Natural Product-Based Interventions and Implications for Personalized Therapy.
10-nov-2026
novelty 2
per-area 2
strengthens
The neuro-inflammaging triangle: a self-amplifying circuit of protein pathology, senescence-associated secretory phenotype and innate immunity in neurodegenerative disease.
10-nov-2026
novelty 3
per-area 2
mentions
A Supplement Kills Senescent Cells and Extends Life in Mice
10-nov-2026
novelty 4
per-area 4
strengthens
Cepharanthine Identified as a Novel Senolytic
10-nov-2026
novelty 3
per-area 3
strengthens
Senescence-targeted engineered CAR-T immunotherapy: advances, challenges and perspectives for engineered senolytic immunotherapy.
09-nov-2026
novelty 3
per-area 3
strengthens
Fatty acid desaturation controls cellular fate decisions between senescence and ferroptosis.
02-nov-2026
novelty 4
per-area 4
strengthens
Enabling Photoacoustic Imaging and Photothermal Elimination of Senescent Cells via an Activatable Theranostic Probe.
01-nov-2026
novelty 3
per-area 3
strengthens
Tree Shrew as an Emerging Model for Aging Research: Characterization of Senescence and Therapeutic Interventions.
01-nov-2026
novelty 4
per-area 4
strengthens
Intervening in Adipocyte Senescence: Lipid Prodrugs as an Emerging Strategy for Metabolic Disease Treatment.
29-oct-2026
novelty 3
per-area 3
strengthens
Olfactory Receptor 51E2 Activation by β-Ionone Induces a Senescence-Like Phenotype and Increases Susceptibility to Senolytic Treatment in Colorectal Cancer.
23-oct-2026
novelty 3
per-area 3
strengthens
Decoding the immune regulation of ovarian aging: mechanisms and therapeutic strategies.
09-oct-2026
novelty 3
per-area 2
mentions
Organoids for modeling cellular senescence and age-related pathology: From experimental reconstruction to mechanistic and translational applications.
08-oct-2026
novelty 2
per-area 2
mentions
Biomarker-Guided, Stage-Specific Senotherapy for Metabolic Dysfunction-Associated Steatotic Liver Disease.
08-oct-2026
novelty 3
per-area 3
strengthens
Is there a role for senotherapeutics in the treatment of giant cell arteritis?
07-oct-2026
novelty 2
per-area 2
mentions
Nanoparticle-based senolytic and senomorphic therapies for healthy aging: design principles, translational evidence, and challenges.
07-oct-2026
novelty 3
per-area 3
strengthens
Treatment benefit does not establish senolysis or lifespan extension.
06-oct-2026
novelty 2
per-area 2
weakens
Endothelial TLR4 at the Crossroads of Vascular Senescence and Targeted Senotherapeutics
06-oct-2026
novelty 2
per-area 2
strengthens
Novel Flavonoid Senotherapeutics Identified by Phenotypic Drug Discovery Reduce Senescence and Improve Multiple Markers of Healthspan
06-oct-2026
novelty 3
per-area 3
strengthens
Therapeutic reversal of cellular senescence: A systematic review of senolytics, senomorphics and anti-ageing therapies in human clinical trials.
05-oct-2026
novelty 3
per-area 3
strengthens
Senotherapeutic potential against xeroderma pigmentosum.
05-oct-2026
novelty 3
per-area 3
strengthens
Orthogonal Light- and Enzyme-Triggered and-Gate Prodrugs for Senolytic Therapy.
04-oct-2026
novelty 3
per-area 3
strengthens
Immunosenescence in tumor progression: from synergistic mechanisms to therapeutic strategies.
03-oct-2026
novelty 2
per-area 2
mentions
Cellular senescence: six decades of discovery and reinvention.
02-oct-2026
novelty 2
per-area 2
strengthens
Endothelial TLR4 at the Crossroads of Vascular Senescence and Targeted Senotherapeutics.
01-oct-2026
novelty 3
per-area 3
strengthens
Novel Flavonoid Senotherapeutics Identified by Phenotypic Drug Discovery Reduce Senescence and Improve Multiple Markers of Healthspan.
01-oct-2026
novelty 3
per-area 3
strengthens
The Intersection of Immunosenescence, Cellular Senescence, and Type 1 Diabetes: Paving the Way for Future Interventions.
01-oct-2026
novelty 3
per-area 2
mentions
Future directions of osteoanabolic therapies in osteoporosis: Integrating current anabolic agents and emerging senescence-targeted strategies.
01-oct-2026
novelty 2
per-area 3
strengthens
Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial.
01-oct-2026
novelty 4
per-area 4
strengthens
uPAR-Targeting T Cell Engager Exerts Senolytic Effects in Mice and Non-Human Primates With Serum Aminotransferase Activity as a Safety Monitor.
01-oct-2026
novelty 4
per-area 4
strengthens
An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer
30-sep-2026
novelty 3
per-area 3
strengthens
Wound Healing, Senescence, and Senotherapeutics.
30-sep-2026
novelty 2
per-area 2
strengthens
Crosstalk between exosomes and cellular senescence: A core vicious loop promoting α-synuclein pathology in Parkinson's disease.
30-sep-2026
novelty 2
per-area 2
strengthens
uPAR‐Targeting T Cell Engager Exerts Senolytic Effects in Mice and Non‐Human Primates With Serum Aminotransferase Activity as a Safety Monitor
29-sep-2026
novelty 4
per-area 4
strengthens
Autologous cytokine-induced NK cells as candidate cellular senolytics: evidence, obstacles, and the experiments still needed.
29-sep-2026
novelty 3
per-area 3
strengthens
Long-Term Human Skin Platform for Modeling Chronic Inflammation, Environmental Stress, and Therapeutic Intervention.
29-sep-2026
novelty 3
per-area 3
strengthens
Stem cell senescence as a regenerative bottleneck in age-related skeletal degeneration: Mechanistic crosstalk and translational strategies.
27-sep-2026
novelty 2
per-area 2
strengthens
T-cell senescence and immunosenescence in chronic oral mucosal inflammatory diseases: mechanisms and therapeutic implications.
27-sep-2026
novelty 2
per-area 1
mentions
Fisetin to Improve Vascular Function in Older Adults
25-sep-2026
novelty 3
per-area 3
strengthens
Senolytics for Cancer treatment: complexities and opportunities.
23-sep-2026
novelty 2
per-area 2
weakens
Engineered Extracellular Vesicle Revitalizing Macrophage Energy Metabolism for Aged Wound Repair.
23-sep-2026
novelty 3
per-area 3
strengthens
The role of senescence in kidney ageing, injury and fibrosis.
23-sep-2026
novelty 2
per-area 2
strengthens
Senescence-associated extracellular vesicles in skin aging and regeneration: from pathophysiology to therapeutic opportunities.
22-sep-2026
novelty 2
per-area 2
strengthens
Cellular senescence and the SASP in skeletal ageing: convergent mechanisms of progressive bone loss in osteoporosis.
22-sep-2026
novelty 2
per-area 3
strengthens
Aging of Skeletal Muscle: From Molecular Mechanisms to Therapeutic Interventions.
21-sep-2026
novelty 2
per-area 2
strengthens
Bone Aging and Glycative Stress: Convergent and Divergent Mechanisms Driving Skeletal Deterioration.
20-sep-2026
novelty 2
per-area 2
mentions
3D-Printed and Biofabricated Scaffolds for Osteoporotic Bone Defect Repair: Mechanical Adaptation, Redox Control, Senescence Modulation and Osteoimmunomodulation.
19-sep-2026
novelty 3
per-area 2
mentions
Therapeutic Targeting of Inflammaging and Emerging Strategies for Managing Age-Related Multimorbidity: A Narrative Review.
19-sep-2026
novelty 2
per-area 2
strengthens
mTOR signaling in aging: from causality to geroprotective interventions and hallmark-level outcomes.
19-sep-2026
novelty 2
per-area 2
mentions